repirinast

10/01/1986 - "Effects of MY-5116 on experimental asthma in rats and guinea pigs."
11/01/1992 - "In 14 patients with mild, stable, atopic asthma, we performed a double-blind, double-dummy, random-order trial with ingested repirinast 300 mg twice daily for 7 days, inhaled cromolyn 40 mg spincaps single dose, and double placebo on allergen-induced early (EAR) and late (LAR) asthmatic responses and increased airway responsiveness. "
04/01/1991 - "[The influence of repirinast, an anti-allergic drug, on theophylline pharmacokinetics in patients with bronchial asthma]."
04/01/1991 - "In order to clarify whether repirinast, an inhibitor of chemical mediator release, could influence the pharmacokinetics of theophylline, a loading test using intravenous injection of aminophylline was performed in 10 subjects with bronchial asthma before and after treatment with 300 mg/day of repirinast. "
11/01/1992 - "In these models, a 1-week treatment period with repirinast, like other oral antiallergic asthma medications (e.g., ketotifen, fumarate), provides no protection against airway responses to methacholine or allergen."

09/01/1986 - "From these results, it is concluded that MY-5116 selectively suppresses the experimental models of type I allergic reaction."
09/01/1986 - "[Effects of MY-5116 on experimental animal models of type I-type IV allergic reactions and the formation of IgE antibody]."
09/01/1986 - "MY-5116 showed no inhibition on the reversed cutaneous anaphylaxis in rats (type II), the Forssman reaction in guinea pigs (type II), the Arthus reaction in mice (type III) and the delayed type hypersensitivity in mice (type IV). "
09/01/1986 - "The effects of a new anti-allergic agent, MY-5116: isoamyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano [3,2-c] quinoline-2-carboxylate, on experimental animal models of type I approximately type IV allergic reactions and the formation of IgE antibody were investigated. "
09/01/1996 - "In order to determine the mast cell requirements in murine delayed-type hypersensitivity (DTH), the effects of the antihistamine chlorpheniramine, the inhibitor of mast cell degranulation repirinast (CAS 73080-51-0, MY-5116), the lipoxygenase and cyclooxygenase inhibitor BW-755C (3-amino-1-[m-(trifluoromethyl)phenyl]-2-pyrazoline), and the cyclooxygenase inhibitors ibuprofen, diclofenac and phenylbutazone on murine DTH reactions were examined. "

01/01/1994 - "She developed urticaria immediately after an irradiation with 1.5 J/cm2 of UVA, and the provocation test confirmed that repirinast was responsible for the urticarial reaction. "

01/01/1993 - "The inhibitory effect of repirinast on the infiltration of eosinophils and/or neutrophils into the airway may reflect the inhibition of late pulmonary response and airway hyperresponsiveness."
01/01/1993 - "Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs."
01/01/1993 - "Repirinast also blocked antigen-induced airway hyperresponsiveness to inhaled acetylcholine. "

01/01/1993 - "The same dose of repirinast significantly inhibited bronchoalveolar lavage eosinophilia and neutrophilia 5 h after antigen challenge (at the peak of the late response). "